Lucerne, Switzerland 
contact@nemooai.com
“TOWARDS CURE” (CR / R) FOR MOST PATIENTS
Targeting far higher levels of efficacy in cancer care
We Aspire to Cure Cancer. We stay very disciplined in our thinking and assumptions about what our significant, expected contributions can be – re-evaluate and learn constantly (AI). We use AI extensively. In all we do. Daily, with programmed own algorithms, leading AI with updates every 6 months (Stanford, MIT, Oxford). We go deep, “iteratively”, and test our main and evolving assumptions with AI. We decide systematically and from a medical, immunological and AI perspective and apply human judgment and OL and nurses’ signals (incl. intuition). We add financial and medical risk parameters mid-term. We decide – and go for it !
BIOENGINEERING & IP
We define the product (science, IP) and therapy approach, do the medical modelling (with AI, KOLs) over 5-8 years. Open, learning, integrating. We use existing data (AI), create, and complement with small tests and studies where needed. We listen and work carefully with EMA, FDA – iteratively, and as partners.
CLINICAL & TIME TO MARKET
We choose and set therapies up (AI), assure “end-to-end” financing until defined endpoints. Then we work and realise the value. We consult with EMA and FDA early – and agree upfront with them. We run clinical trials in smartest and lowest cost ways possible (at 30-35%, due to SWISSEXEL.COM & Nemoo AI-daptive© clinical trials approach). 18 months in advance, we plan for deals, exits or launches. We aspire to return very nicely to investors. We are skilled, low cost, quality, speed and low risks focused, not money driven. Hence, we can deliver to all that are part of it.
Introduction to AMEDIOO Health EDC
“We work where we work best.”
We own an independent and thorough understanding of our technologies from leading Universities in Europe (Vienna, MHH Hannover, Heidelberg, Dana Faber, Boston, USA). We are managed by ETH Zurich and from Lucerne, Switzerland, with an experienced management (Head of EMEA Oncology of AstraZeneca, London, and Executive Head of Europe, Parexel (CRO), Berlin, EU). We apply AI supported immunology to transform today’s key sectors of cancer care. We work where we can “cure or move much closer to cure” (CR / R). The governing company of AMEDIOO Health EDC is SWISS IMMUNE EDC – where we structure things, indications, solutions and investments.
We also founded a “Major Cancer Types” company with “meedioo.com” in cooperation with future US and EU centers and OLs – as competition and logic, combinations are different in these major cancer types.
We also founded an own, specific “cancer specific” NEMOO AI companies’ clinical trials’ organisation, as we could not get services on the market. We are an IO based, lower costs, high speed and “smart AI” university center driven development & commercialisation company (swissexel.com). Based on our experiences and knowledge, while integrating AI deeper and smarter in than others (swissexel.com), we develop 2-3 years faster and at only 30-35% of standard costs with centres. This gives investors an additional (X-) multiplier on financial returns (ROI) of x 3.5 to above x 6. So a 2-fold return can become a 7-12 fold return, faster and at lower costs.
We assess with our technologies, structure and select well our cancer types (go back and test). We only ask for complete “financing end-to-end” until positive Phase II results or to other endpoints (e.g. earlier exits, partnering, pre-IPOs or sale of indication after 1st commercialisation).
We are honest and work hard. Others we do not choose. We are an EDC – ethics driven company, a new concept for investing into hightech and breakthrough technologies (University of Zurich). Our financial plan is our business plan – and we track and report. We live honesty, transparency, smartness, excellence in what we do, openness and “rapid team-work”.
We aim for speed, quality, precision & team-work
various tissues & cancer types
high medical need & lack of options (EDC)
major cancer types with improvements
Ambition is to reach “cure” (CR/R) for most patients
27
YEARS
OF SCIENTIFIC, CLINICAL WORK,
NIH GRANTS
“TOWARDS CURE” (CR) FOR MORE PATIENTS
Higher Efficacies in
20 selected Cancer Types
We only work where our products and technologies work best. We focus inside areas on synergies to reduce costs and risk. We use AI and regulatory advise (FDA, EMA) extensively. It is a “unique, simple and powerful approach” to deliver breakthroughs, our “best “shots and skills” towards “curing cancer“
Amedioo Pelvic ©
We perceive the “gaps to cure” mostly closable and aim at far higher efficacy rates (CR, R) in:
. AP1 Vulva Cancer
. AP2 Vaginal Cancer
. AP3 Penile Cancer
. AP4 Ovarian Cancer
. AP5 Colorectal Cancer
. AP6 Cervical Cancer
. AP7 Anal & Rectal Cancer
Amedioo Thoracic ©
We perceive the gaps to cure closable and aim at far higher efficacy rates (CR, R) in:
. AT1 Large Cell (LCC)
. AT2 Lung nodular (LNC)
. AT3 NSC Adeno C
. AT4 NSC Squamous C
. AT5 SCLC Small Cell C
. AT6 SCLC Combined Small
. Cell Cancer (SCCC)
.
Amedioo Melanoma ©
We perceive gaps to cure “difficult but closable” with new technologies and AI and far better treatment approaches (CR, R) in:
. AM1 Melanoma (pigment)
. AM2 Basal Cell (BCC)
. AM3 Squamous Cell (SCC)
. AM4 Merkel Cell
. (neuro endocrine)
. AM5 Kaposi Sarcoma
. (immunocompromised)
Amedioo Rare © (SwissOrphan.com)
We perceive curing “rare cancers” esp. in children (next to no approved therapies) “truly achievable” and an “ethical imperative”. We aim at highest rates of cure for “the few” (CR, R):
. AR1 = AP1
. AR2 Liposarcomas
. AR3 = AP3
. AR4 = AP4
. AR5 = AP7
. AR6 Mesoteliomas
Therapies for rare cancers follow different regulatory paths and strategies. We manage them separately with our regulatory affairs capabilities (Swissexel, EMA, FDA).
swissorphan.com
swissexel.com
swissexel.com
MAJOR CANCER INDICATIONS
We separated further out
5 major cancer types (“Big Five”)
We only work where our products and technologies work best. Some we need to complement. We also try to “crack the biggest cancer types” with new technologies and “AI driven Smartness” (Swissexel.com): Pancreatic (PC), Non Small Cell Lung (NSCLC) and e.g. Prostate Cancer. This requires bigger partnerships esp. in Phase II with newer technologies by others, too. We look ahead around 5 to 8 years in cancer R&D. Hence, we summarised those “Big 5” under “MEEDIOO.COM“). In these areas, NEMOO AI Value Builders EDC is demanded to find and partner with other companies. It is a major BD engagement effort in each cancer type. Still exploratory (2023-25) but moving ahead, these represent medical and commercial options once we have delivered main indications above (2027+).
EDC – Ethics Driven Companies
We aspire to assure end-to-end financing for our indications by NEMOO AI, with reviews & financial value updates
As part of EDC companies, we were developed by NEMOO AI Value Builders EDC AG. We continue to benefit from their support and coaching, their structure, networks and governance. We jointly develop our projects, people, teams, indications, new breakthrough products and add simple AI solutions for doctors where needed. We meet for future growth opportunities, creatively, selectively and often
Best Experience
Our team is very solid, science, development, medical, launches and finance
Right Capital
We partner closely with our investors, their goals, to create more value for them & patients, calmly.
contact@
nemooai.com
NEMOO AI Value Builders EDC AG is the founding “partner” supporting us on any corporate matters, IP and financing.
LEADERSHIP & GOVERNANCE
Experienced Team –
AMEDIOO.COM
We follow the medicine, science and numbers – for solid, risk reduced or mitigated returns for our entrusted investors and patients to be cured.
Our core team combines a variety of backgrounds and skills, practical and operational experience from drug development (Parexel), regulatory affairs (Parexel), pharmaceuticals (Roche, Biogen, AstraZeneca) and biotechnology (Amgen, Biogen), manufacturing (Honza), scientific & clinical development (NovoNordisk, Roche, Parexel), finance & taxation (SP-Merck & Co.) and global leadership and management (Roche, AZ, Biogen, Cubist, Sobi)
We are “passionate” about curing cancer (CR / R) and “aspire to deliver”
Sara (18) and Christian (founders)
Zurich 2025+ & Lucerne, 2016-2025+, Switzerland
